Peter Sondermann

Company: Tacalyx GmbH

Job title: CEO

Seminars:

Antibody-Targeting of Tumour-Associated Carbohydrate Antigens (TACAs) for Passive Immunotherapies 1:30 pm

Presenting TACAs as a novel class of targets exclusively expressed on tumour cells Uncovering how TACAs drive tumour progression by mediating metastasis, induction of angiogenesis or down-modulation of the immune system and therefore are ideal targets to interfere with tumour progression and targeting for antibody-mediated cell killing Outlining Tacalyx’s technology which allows the generation and…Read more

day: Day Two